CN114249733B - 一种Isaindigotone衍生物及其在制备抗肿瘤药物中的应用 - Google Patents
一种Isaindigotone衍生物及其在制备抗肿瘤药物中的应用 Download PDFInfo
- Publication number
- CN114249733B CN114249733B CN202110808629.9A CN202110808629A CN114249733B CN 114249733 B CN114249733 B CN 114249733B CN 202110808629 A CN202110808629 A CN 202110808629A CN 114249733 B CN114249733 B CN 114249733B
- Authority
- CN
- China
- Prior art keywords
- isaindigotone
- derivative
- cancer
- hydrogen
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及药物化学技术领域,尤其涉及一种Isaindigotone衍生物及其制备抗肿瘤药物中的应用。本发明首先提供了一类Isaindigotone衍生物;其次,本发明通过体外MTT抗肿瘤活性研究发现,所述Isaindigotone衍生物对胃癌、结直肠癌、肝癌、胰腺癌等多种癌症细胞均具有良好的抑制作用;尤其是所述Isaindigotone衍生物能够显著抑制胃癌细胞的增值,抑制胃癌细胞的活性,具有显著的治疗胃癌的效果,且其药效显著高于现有一线抗癌药物Pt,在制备抗癌药物中具有广泛的应用前景。
Description
技术领域
本发明属于药物化学领域,具体涉及一种Isaindigotone衍生物及其制备方法和在制备抗 癌药物中的应用。
背景技术
胃癌治疗方案的选择主要是基于病程,出现的生物标志物,以及临床病征。胃癌早期患 者通常通过切除手术以治疗恶性肿瘤。手术类型取决于肿瘤浸润的位置和深度,包括内镜粘 膜切除术,食管远端切除术,胃次全切除术或全胃切除术。研究显示,相比于单纯手术切除, 二期和三期的胃癌患者接受辅助治疗后的生存率更高。目前,晚期胃癌的治疗主要是通过姑 息化疗改善症状。晚期胃癌化疗药物主要有紫杉醇类(紫杉醇和多西他赛)、氟尿嘧啶类(5 -氟尿嘧啶、替吉奥、卡培他滨)、铂类(顺铂和奥沙利铂)、伊立替康、表柔沙星等,且多以 氟尿嘧啶联合铂类为一线化疗方案。
在过去的十多年中,伴随着诸如高通量筛选和组合化学这样的新型技术的出现,在新药 的探索的过程中,天然产物受到越来越广泛的关注。统计显示,从1940年到2002年间获批 的抗肿瘤药物,大约54%都是来自于天然产物或者受到相关化合物得到启示研究开发所得。 因此基于天然产物的药物开发具有广阔前景。
PI3K/AKT/mTOR作为一条经典的抗凋亡信号转导通路,与细胞内诸如细胞增殖,迁移等多 种正常的生理活动密切相关。与其它肿瘤类似,胃癌中也存在着PI3K/AKT/mTOR通路异常。 综上所述,PI3K/AKT/mTOR通路在胃癌组织中的过度激活提示我们这条通路中的相关蛋白 可以作为抗肿瘤治疗的靶点。
Isaindigotone是从中药板蓝根中提取得到的一种喹唑啉酮衍生物,是由喹唑啉酮与苯亚 甲基连接而成。本发明合成了一类新的Isaindigotone衍生物,所述Isaindigotone衍生物具有 抗癌活性,能够靶向AKT蛋白,对胃癌、结直肠癌、肝癌、胰腺癌等具有良好的抑制作用, 显著高于现有一线抗癌药物Pt,在制备抗癌药物中具有广泛的应用空间。
发明内容
针对上述问题,本发明的目的在于提供一种新的Isaindigotone衍生物,及其在制备抗癌 药物中的应用,具体包括以下内容:
第一方面,本发明提供了一种Isaindigotone衍生物或其药学上可接受的盐,其特征在于, 所述Isaindigotone衍生物结构式如下式(I)所示:
其中,
当所述n为1,所述R1和R2为氢时,所述R3和R4为氟、R5为氢,或所述R3和R5为氢、 R4为三氟甲氧基,或所述R3和R5为三氟甲基、R4为氢;
当所述n为1,所述R1为氢,R2为氟时,所述R3、R4和R5为甲氧基,或所述R3和R4为氟、R5为氢,或R3和R5为三氟甲基、R4为氢;
当所述n为1,所述R1和R2为氟时,所述R3和R5为氢、R4为三氟甲氧基,或所述R3和R5为三氟甲基、R4为氢;
当所述n为1,所述R1为氟,R2为氢时,所述R3和R4为氟、R5为氢,或所述R3和R5为甲氧基、R4为羟基,或所述R5为氢、R3和R4形成1,3-二氧五环;
当所述n为1,所述R1和R2为甲氧基时,所述R3和R4为氟、R5为氢,或所述R3和R5为氢、R4为氟,或所述R3和R5为氢、R4为三氟甲基,或所述R3为氢,R4和R5形成1,3-二 氧五环;
当所述n为1,所述R1为甲氧基,R2为4-甲基哌嗪基时,所述R3和R5为氢、R4为三氟 甲基,或所述R3为氢、R4和R5为氟;
当所述n为2,所述R1和R2为氢时,所述R3和R5为氢、R4为氟,或所述R3和R5为甲 氧基、R4为羟基;
当所述n为2,所述R1为氟,R2为氢时,所述R3、R4和R5为甲氧基,或所述R3和R5为氢、R4为氟,或所述R5为氢、R3和R5形成1,3-二氧五环。
第二方面,本发明提供了一种上述第一方面所述的Isaindigotone衍生物或其药学上可接 受的盐在制备治疗癌症药物中的应用。
优选地,所述癌症包括胃癌、结直肠癌、肝癌、胰腺癌。
优选地,所述癌症为胃癌,所述Isaindigotone衍生物包括以下所示化合物:
优选地,所述Isaindigotone衍生物为:
优选地,所述Isaindigotone衍生物为:
优选地,所述癌症为胰腺癌,所述Isaindigotone衍生物包括以下所示化合物:
优选地,所述癌症为胰腺癌,所述Isaindigotone衍生物为:
优选地,所述癌症为结肠癌,所述Isaindigotone衍生物包括以下所示化合物:
优选地,所述Isaindigotone衍生物的结构式为:
优选地,所述癌症为肝癌,所述Isaindigotone衍生物的结构式如下所示:
优选地,所述的Isaindigotone衍生物或其药学上可接受的盐,加入药学上可接受的辅料 制成药学上可接受的任一剂型。
本发明的有益效果是:本发明首先提供了一类Isaindigotone衍生物;其次,本发明通过 体外MTT抗肿瘤活性研究发现,所述Isaindigotone衍生物对胃癌、结直肠癌、肝癌、胰腺癌 等多种癌症细胞均具有良好的抑制作用;尤其是所述Isaindigotone衍生物能够显著抑制胃癌 细胞的增值,抑制胃癌细胞的活性,具有显著的治疗胃癌的效果,且其药效显著高于现有一 线抗癌药物Pt,在制备抗癌药物中具有广泛的应用空间。
附图说明
为了更清楚地说明本发明实施例的技术方案,下面将对实施例中所需要使用的附图作简 单地介绍,应当理解,以下附图仅示出了本发明的某些实施例,因此不应被看作是对范围的 限定,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图 获得其他相关的附图。
图1 Isaindigotone衍生物的合成路线图;
图2 Isaindigotone衍生物BLG06对胃癌细胞体外抗增殖活性的影响结果;
图3 Isaindigotone衍生物BLG06对胃癌AGS细胞形态的影响结果;
图4 Isaindigotone衍生物BLG06对胃癌AGS细胞周期及凋亡的影响结果;
图5 Isaindigotone衍生物BLG06对线粒体(MMP)膜电位变化的影响结果;
图6分子对接及蛋白质印迹实验结果;
图7 Isaindigotone衍生物BLG06抑制AGS细胞迁移的结果。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将对本发明实施例中的技术 方案进行清楚、完整地描述。实施例中未注明具体条件,按照常规条件或制造商建议的条件 进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
以下实施例所用的人癌细胞系包括结直肠癌细胞系HCT116、胃癌细胞系AGS、胰腺癌 细胞系PANC-1、肝癌SMMZ-7721以及正常胃细胞系GES-1;所述HCT116、AGS、PANC- 1购自ATCC(美国);所述SMMZ-7721和GES-1购自兰州大学药学院。除HCT116、AGS、 SMMZ-7721细胞系在1640培养基(1640,Solarbio Invitrogen Corp.,Beijing,China)中培 养;PANC-1和GES-1细胞系在高糖培养基(DMEM,Solarbio Invitrogen Corp.,Beijing,C hina)中培养;培养条件为:37℃、5%CO2条件,所有细胞都补充有10%胎牛血清(FBS)、 100U/mL青霉素和100mg/mL链霉素。
实施例1 Isaindigotone衍生物的制备
Isaindigotone衍生物的合成路线如图1所示,合成的Isaindigotone衍生物分别用BLG01- 22表示,合成的Isaindigotone衍生物的结构式如下表1所示:
(1)b1-b7的合成:在室温下,将45mL POCl3小心地添加到各种2-氨基苯甲酸(a1-5,19.30mmoL,1eq)和吡咯烷-2酮或2-哌啶酮(38.60mmoL,2eq)的混合溶液中;然后 将混合物在110℃搅拌7h;减压除去POCl3后,将残余物倒入冰水中,然后加入NaOH溶液 使溶液呈碱性;混合物用3×50mL的CH2Cl2萃取;合并的有机相用MgSO4干燥,真空浓缩, 然后通过快速柱纯化,用石油醚/EtOAc(4:1)洗脱,得到白色固体。
(2)b8的合成:将催化量的Na2CO3加入到中间体b4(15.00mmoL)和N-甲基哌嗪(4.00mL)的DMF(36.00mL)溶液中;然后将混合物在140℃搅拌2h;减压除去部分DMF 后,将残渣倒入30.00mL水中,过滤,水洗,得到白色固体。
(3)BLG01-BLG22的合成:将催化量的NaOAc加入到中间体b1-b8(10.00mmoL)和 不同取代的苯甲醛(c1-7,20.00mmoL),AcOH(70.00mL)溶液中;然后将混合物在115℃ 下搅拌6h;减压除去部分AcOH后,将残余物倒入15.00mL冰冷的丙酮中,然后过滤并用 丙酮洗涤,得到白色或黄色固体。
得到的化合物分别用BLG01-BLG22表示,其中BLG01-BLG22的谱图数据如下所示:
BLG01:(E)-3-(3,4-difluorobenzylidene)-2,3-dihydropyrrolo[2,1-b]quinazolin-9(1H)-one;Yi eld:69%;yellow solid,m.p.218-220℃;1H NMR(400MHz,CDCl3)δ:8.29(d,J=7.9 Hz,1H),7.87–7.63(m,3H),7.45(m,1H),7.37(m,1H),7.27(m,2H),4.31(t,J=7. 2Hz,2H),3.26(t,J=7.4Hz,2H).13C NMR(100MHz,CDCl3)δ:161.11,155.03,15 1.66(d,J=13.0Hz),149.54,149.19(d,J=12.8Hz),134.32,132.56(d,J=2.8Hz),1 28.37(d,J=2.3Hz),127.34,126.44,126.41,120.95,118.12,117.94,117.92,117.74,44.0 0,25.34.MS-ESI m/z:calcd for C18H12F2N2O[M+H]+:311.0918;found:311.0985.
BLG02:(E)-3-(4-(trifluoromethoxy)benzylidene)-2,3-dihydropyrrolo[2,1-b]quinazolin-9(1H)- one;Yield:73%;yellow solid,m.p.174-175℃;1H NMR(400MHz,CDCl3)δ:8.29(d, J=8.0Hz,1H),7.82(d,J=3.0Hz,1H),7.75(d,J=4.1Hz,2H),7.58(d,J=8.4Hz, 2H),7.44(m,1H),7.36–7.12(m,2H),4.30(t,J=7.2Hz,2H),3.27(t,J=7.4,2H). 13C NMR(100MHz,CDCl3)δ:161.15,155.19,149.59,149.26,134.29,134.10,132.48,131.10,128.97,127.33,126.43,126.34,121.12,120.95,44.00,25.44.MS-ESI m/z:calcdfo r C19H13F3N2O2[M+H]+:359.0929;found:359.0986.
BLG03:(E)-3-(3,5-bis(trifluoromethyl)benzylidene)-2,3-dihydropyrrolo[2,1-b]quinazolin-9(1 H)-one;Yield:76%;yellow solid,m.p.318-320℃;1H NMR(400MHz,CDCl3)δ:8.33 (d,J=8.0Hz,1H),7.98(s,2H),7.93(s,1H),7.87(s,1H),7.78(d,J=2.1Hz,2H),7. 50(m,1H),4.36(t,J=7.1Hz,2H),3.35(t,J=7.5Hz,2H).13C NMR(100MHz,C DCl3)δ:161.05,137.46,135.82,134.46,132.58,132.24,129.03,129.01,127.57,127.18,1 26.81,126.51,122.06,121.73,121.11,44.01,25.46.MS-ESI m/z:calcd for C20H12F6N2O [M+H]+:411.0854;found:411.0877.
BLG04:(E)-6-fluoro-3-(3,4,5-trimethoxybenzylidene)-2,3-dihydropyrrolo[2,1-b]quinazolin-9 (1H)-one;Yield:85%;yellow solid,m.p.212-214℃;1H NMR(400MHz,CDCl3)δ:8.28 (dd,J=8.8,6.2Hz,1H),7.77(d,J=2.9Hz,1H),7.36(dd,J=9.9,2.5Hz,1H),7.1 4(m,1H),6.80(s,2H),4.30(t,J=7.3Hz,2H),3.92(d,J=2.4Hz,9H),3.38(t,J= 7.3Hz,2H).13C NMR(100MHz,CDCl3)δ:160.54,156.77,153.38,139.40,131.54,130. 85,130.14,128.96(d,J=10.7Hz),117.58,114.87(d,J=8.4Hz),114.68,112.36(d,J =21.7Hz),112.07,107.41,61.01,56.30,44.07,25.42.MS-ESI m/z:calcd forC21H19FN2 O4[M+H]+:383.1329;found:383.1378.
BLG05:(E)-3-(3,5-bis(trifluoromethyl)benzylidene)-6-fluoro-2,3-dihydropyrrolo[2,1-b]quina zolin-9(1H)-one;Yield:80%;yellow solid,m.p.208-209℃;1H NMR(400MHz,CDCl3) δ:8.31(dd,J=8.8,6.1Hz,1H),7.98(s,2H),7.92(t,J=3.0Hz,1H),7.88(s,1H),7. 39(dd,J=9.7,2.5Hz,1H),7.19(t,J=8.5Hz,1H),4.35(t,J=7.1Hz,2H),3.35(t, J=7.2Hz,2H).13C NMR(100MHz,CDCl3)δ:167.85,165.32,160.33,155.61,151.6 6(d,J=13.1Hz),137.27,135.48,132.45(d,J=33.6Hz),129.57-128.55(m),127.86, 124.41,122.23(d,J=4.3Hz),121.70,117.82,115.51(d,J=23.7Hz),112.75(d,J= 22.0Hz),44.06,25.43.MS-ESI m/z:calcd for C20H11F7N2O[M+H]+:429.0760;found:4 29.0565.
BLG06:(E)-3-(3,4-difluorobenzylidene)-6-fluoro-2,3-dihydropyrrolo[2,1-b]quinazolin-9(1H) -one;Yield:83%;yellow solid,m.p.243-245℃;1H NMR(400MHz,CDCl3)δ:8.31(dd, J=8.8,6.2Hz,1H),7.77(d,J=2.6Hz,1H),7.38(dd,J=9.7,2.5Hz,1H),7.31(m, 1H),7.26(m,1H),7.17(m,1H),4.31(t,J=7.3Hz,2H),3.29(t,J=7.3Hz,2H).13 C NMR(100MHz,CDCl3)δ:160.45,158.60,156.27,151.84(d,J=13.6Hz),151.65,1 29.09(d,J=4.5Hz),128.96,126.53,126.47,118.12(d,J=18.8Hz),117.98,117.75(d, J=9.9Hz),115.24,115.01,112.66,112.44,44.04,25.34.MS-ESI m/z:calcdfor C18H11 F3N2O[M+H]+:329.0823;found:329.0700.
BLG07:(E)-6,7-difluoro-3-(4-(trifluoromethoxy)benzylidene)-2,3-dihydropyrrolo[2,1-b]quina zolin-9(1H)-one;Yield:72%;yellow solid,m.p.167-169℃;1H NMR(400MHz,CDCl3) δ:8.04(dd,J=10.0,8.5Hz,1H),7.81(t,J=2.9Hz,1H),7.68-7.55(m,2H),7.51(d d,J=10.9,7.0Hz,1H),7.31(d,J=8.3Hz,2H),4.63-4.07(m,2H),3.30(t,J=7.3 Hz,2H).13C NMR(100MHz,CDCl3)δ:159.78,156.27,155.98,149.44,133.84,131.92, 131.19,129.72,121.69,121.17,117.81,115.01,114.84,113.86,113.68,44.17,25.39.MS- ESI m/z:calcd for C19H11F5N2O2[M+H]+:395.0741;found:395.0612.
BLG08:(E)-3-(3,5-bis(trifluoromethyl)benzylidene)-6,7-difluoro-2,3-dihydropyrrolo[2,1-b]qu inazolin-9(1H)-one;Yield:79%;yellow solid,m.p.216-218℃;1H NMR(400MHz,CDCl 3)δ:1H NMR(400MHz,Chloroform-d)δ8.06(dd,J=10.0,8.5Hz,1H),7.98(s,2H), 7.89(s,1H),7.52(dd,J=10.8,7.0Hz,1H),4.35(t,J=7.1Hz,2H),3.36(t,J=7.3 Hz,2H).13C NMR(100MHz,CDCl3)δ:159.66,156.26(d,J=14.8Hz),155.15(d,J =2.5Hz),153.70(d,J=14.6Hz),150.92(d,J=14.4Hz),148.41(d,J=14.4Hz),14 7.23(d,J=9.7Hz),137.20,135.25,132.48(d,J=33.6Hz),129.06,127.86,124.40,122. 57-121.98(m),121.69,118.01(d,J=6.4Hz),115.17(d,J=17.9Hz),113.87(dd,J= 19.3,2.5Hz),44.17,25.39.MS-ESI m/z:calcd for C20H10F8N2O[M+H]+:447.0665;fo und:447.0503.
BLG09:(E)-7-fluoro-3-(4-hydroxy-3,5-dimethoxybenzylidene)-2,3-dihydropyrrolo[2,1-b]qui nazolin-9(1H)-one;Yield:85%;yellow solid,m.p.243-245℃;1H NMR(400MHz,CDCl 3)δ:7.91(dd,J=8.5,3.0Hz,1H),7.82-7.61(m,2H),7.45(m,1H),6.82(s,2H),4.3 0(t,J=7.4Hz,2H),3.95(s,6H),3.47-3.21(m,2H).13C NMR(100MHz,CDCl3)δ: 161.69,160.56,159.23,155.27,147.20,146.46,136.29,131.11,129.29,128.64,127.03,12 2.79(d,J=24.2Hz),121.90(d,J=8.6Hz),111.29(d,J=23.7Hz),107.10,56.39,44. 08,25.43.MS-ESI m/z:calcd for C20H17FN2O4[M+H]+:369.1172;found:369.1040.
BLG10:(E)-3-(benzo[d][1,3]dioxol-5-ylmethylene)-7-fluoro-2,3-dihydropyrrolo[2,1-b]quinaz olin-9(1H)-one;Yield:78%;yellow solid,m.p.288-290℃;1H NMR(400MHz,CDCl3)δ: 7.92(dd,J=8.5,3.0Hz,1H),7.78-7.65(m,2H),7.59-7.39(m,2H),7.09(d,J=8. 5Hz,1H),6.89(d,J=7.5Hz,1H),6.04(s,2H),4.29(t,J=7.4Hz,2H),3.34-3.20 (m,1H).13C NMR(100MHz,CDCl3)δ:160.53,148.32(d,J=20.7Hz),130.57,129.4 0(d,J=8.2Hz),129.01(d,J=7.3Hz),125.40,123.67,122.90,111.29(d,J=23.6H z),110.05,109.01,108.80,108.04,107.73,101.57,101.01,56.05,44.08,25.51.MS-ESI m/ z:calcd for C19H13FN2O3[M+H]+:337.0910;found:337.0950.
BLG11:(E)-3-(3,4-difluorobenzylidene)-7-fluoro-2,3-dihydropyrrolo[2,1-b]quinazolin-9(1H)- one;Yield:84%;yellow solid,m.p.228-230℃;1H NMR(400MHz,CDCl3)δ:7.91(dd, J=8.5,3.0Hz,1H),7.81-7.66(m,2H),7.47(m,1H),7.37(dd,J=10.9,7.6Hz,1 H),7.27(dd,J=13.4,10.0Hz,2H),4.31(t,J=7.2Hz,2H),3.27(t,J=7.4Hz,2H). 13C NMR(100MHz,CDCl3)δ:161.93,160.37(d,J=3.5Hz),159.46,154.53,146.21, 132.52(d,J=5.6Hz),132.25,129.59(d,J=8.1Hz),128.39,126.36(dd,J=6.4,3.5 Hz),122.90(d,J=24.3Hz),122.13(d,J=8.6Hz),118.13,117.95,117.78,111.37(d,J =23.6Hz),44.04,25.35.MS-ESI m/z:calcd for C18H11F3N2O[M+H]+:329.0823;found:329.0889.
BLG12:(E)-3-(benzo[d][1,3]dioxol-5-ylmethylene)-6,7-dimethoxy-2,3-dihydropyrrolo[2,1-b] quinazolin-9(1H)-one;Yield:72%;yellow solid,m.p.289-291℃;1H NMR(400MHz,CD Cl3)δ:7.60(d,J=2.9Hz,1H),7.52(s,1H),7.06(s,1H),7.03-6.93(m,2H),6.81(d, J=8.1Hz,1H),5.95(s,2H),4.20(t,J=7.2Hz,2H),3.94(s,3H),3.93(s,3H),3.25 -3.13(m,2H).13C NMR(100MHz,CDCl3)δ:160.56,154.87,148.65,148.19,145.99, 134.04,129.99,129.68,129.36,126.63,125.13,114.13,111.31,108.93,108.75,107.58,10 5.43,101.52,56.29,44.09,25.61.MS-ESI m/z:calcd forC21H18N2O5[M+H]+:379.1216; found:319.1246.
BLG13:(E)-3-(4-fluorobenzylidene)-6,7-dimethoxy-2,3-dihydropyrrolo[2,1-b]quinazolin-9(1 H)-one;Yield:73%;yellow solid,m.p.271-273℃;1H NMR(400MHz,CDCl3)δ:7.73 (d,J=3.0Hz,1H),7.60(s,1H),7.53(dd,J=8.7,5.5Hz,2H),7.20-7.07(m,3H),4. 30(t,J=7.2Hz,2H),4.02(s,3H),4.00(s,3H),3.36-3.16(m,2H).13C NMR(100 MHz,CDCl3)δ:163.95,160.49,154.91,154.33,148.80,145.87,131.87(d,J=3.4Hz),1 31.4,131.38,128.33,115.99(d,J=21.7Hz),114.25,107.64,105.43,56.31,56.29,44.06, 25.53.MS-ESI m/z:calcd for C20H17FN2O3[M+H]+:353.1223;found:353.1262.
BLG14:(E)-3-(3,4-difluorobenzylidene)-6,7-dimethoxy-2,3-dihydropyrrolo[2,1-b]quinazolin- 9(1H)-one;Yield:76%;yellow solid,m.p.262-264℃;1H NMR(400MHz,CDCl3)δ:7. 67(d,J=2.8Hz,1H),7.61(s,1H),7.35(m,1H),7.32-7.18(m,2H),7.14(s,1H),4. 31(t,J=7.1Hz,2H),4.02(s,3H),4.01(s,3H),3.26(t,J=7.3Hz,2H).13C NMR(1 00MHz,CDCl3)δ:160.41,154.96,153.92,152.24-151.25(m),149.19(d,J=12.2Hz), 148.96,145.78,132.86(d,J=2.6Hz),132.73(d,J=5.4Hz),127.23,126.18(dd,J= 6.3,3.3Hz),117.94(d,J=9.2Hz),117.76(d,J=8.9Hz),114.34,107.68,105.43,56.3 2,56.30,44.05,25.47.MS-ESI m/z:calcd for C20H16F2N2O3[M+H]+:371.1129;found: 371.1169.
BLG15:(E)-6,7-dimethoxy-3-(4-(trifluoromethyl)benzylidene)-2,3-dihydropyrrolo[2,1-b]quin azolin-9(1H)-one;Yield:81%;yellow solid,m.p.256-257℃;1H NMR(400MHz,CDCl3) δ:7.80(t,J=2.8Hz,1H),7.74-7.60(m,5H),7.17(s,1H),4.33(t,J=7.2Hz,2H), 4.03(s,3H),4.02(s,3H),3.32(t,J=7.2Hz,2H).13C NMR(100MHz,CDCl3)δ:160. 44,155.01,153.86,149.09,145.78,138.97,134.56,129.61,127.84,125.79,125.75,114.45, 107.77,105.47,56.35,56.32,53.40,44.07,25.72.MS-ESI m/z:calcd for C21H17F3N2O3 [M+H]+:403.1191;found:403.1145.
BLG16:(E)-3-(3,4-difluorobenzylidene)-7-fluoro-6-(4-methylpiperazin-1-yl)-2,3-dihydropyrr olo[2,1-b]quinazolin-9(1H)-one;Yield:69%;yellow solid,m.p.231-233℃;1H NMR(400 MHz,CDCl3)δ:7.76(d,J=12.9Hz,1H),7.61(d,J=3.1Hz,1H),7.32-7.24(m,1 H),7.23-7.12(m,2H),7.08(d,J=7.8Hz,1H),4.20(t,J=7.1Hz,2H),3.24(t,J= 4.8Hz,4H),3.17(d,J=9.8Hz,2H),2.56(t,J=4.9Hz,4H),2.31(s,3H).13CNM R(100MHz,CDCl3)δ:159.11,154.14(d,J=44.5Hz),151.88,150.65(d,J=12.7Hz),148.16(d,J=16.1Hz),146.51,145.35(d,J=10.0Hz),131.67,126.89,125.27,117.06,116.89,116.73,114.17(d,J=3.6Hz),113.51(d,J=8.4Hz),111.04(d,J=23.7Hz),53.89,48.91(d,J=4.7Hz),45.09,42.93,24.38.MS-ESI m/z:calcd for C23H21F3N4O [M+H]+:427.1667;found:427.1769.
BLG17:(E)-7-fluoro-6-(4-methylpiperazin-1-yl)-3-(4-(trifluoromethyl)benzylidene)-2,3-dihy dropyrrolo[2,1-b]quinazolin-9(1H)-one;Yield:78%;whitesolid,m.p.228-230℃;1H NMR (400MHz,CDCl3)δ:7.83–7.69(m,2H),7.65–7.49(m,4H),7.09(d,J=7.8Hz,1 H),4.21(t,J=7.1Hz,2H),3.23(m,6H),2.56(t,J=4.8Hz,4H),2.31(s,3H).13C NMR(100MHz,CDCl3)δ:159.07(d,J=3.2Hz),154.42,153.82(d,J=2.2Hz),151.9 4,146.49,145.37(d,J=10.1Hz),137.82,133.38,129.40(d,J=32.8Hz),128.66,127.4 3,124.76(q,J=3.8Hz),114.24(d,J=3.6Hz),113.57(d,J=8.5Hz),111.06(d,J=23.8Hz),53.89,48.91(d,J=4.7Hz),45.08,42.94,24.61.MS-ESI m/z:calcd for C24H22F4N4O[M+H]+:459.1730;found:459.1257.
BLG18:(E)-6-(4-hydroxy-3,5-dimethoxybenzylidene)-6,7,8,9-tetrahydro-11H-pyrido[2,1-b]q uinazolin-11-one;Yield:79%;yellow solid,m.p.226-227℃;1HNMR(400MHz,CDCl3) δ:8.36-8.14(m,1H),8.08(d,J=2.1Hz,1H),7.71-7.52(m,2H),7.35(m,1H),6.6 8(s,2H),5.70(s,1H),4.25-4.03(m,2H),3.86(s,6H),2.91(t,J=6.6Hz,2H),1.98 (t,J=10.5Hz,2H).13C NMR(100MHz,CDCl3)δ:161.14,150.95,146.60,145.86,134.80,134.46,133.11,127.16,126.64,126.19,125.66,125.03,119.03,106.39,55.40,41.06, 24.99,21.12.MS-ESI m/z:calcd for C21H20N2O4[M+H]+:365.1423;found:365.1433.
BLG19:(E)-6-(4-fluorobenzylidene)-6,7,8,9-tetrahydro-11H-pyrido[2,1-b]quinazolin-11-one; Yield:85%;yellow solid,m.p.165-166℃;1H NMR(400MHz,CDCl3)δ:8.40 8.23(m, 1H),8.18(d,J=2.2Hz,1H),7.73(dd,J=7.0,1.7Hz,2H),7.45(td,J=8.5,5.7Hz, 3H),7.12(t,J=8.7Hz,2H),4.32-3.93(m,2H),3.03-2.71(m,2H),2.12-1.90(m, 2H).13C NMR(100MHz,CDCl3)δ:163.65,162.12,151.63,147.51,134.19(d,J=4.6 Hz),132.37(d,J=3.4Hz),131.80(d,J=8.1Hz),129.84(d,J=1.7Hz),127.30,126. 68,126.24,120.17,115.61,115.40,42.19,25.71,22.06.MS-ESI m/z:calcd forC19H15FN 2O[M+H]+:307.1168;found:307.1299.
BLG20:(E)-2-fluoro-6-(3,4,5-trimethoxybenzylidene)-6,7,8,9-tetrahydro-11H-pyrido[2,1-b]q uinazolin-11-one;Yield:82%;yellow solid,m.p.164-166℃;1H NMR(400MHz,CDCl3) δ:8.14(d,J=2.2Hz,1H),7.90(dd,J=8.5,3.0Hz,1H),7.72(dd,J=9.0,4.9Hz, 1H),7.46(d,J=3.0Hz,1H),6.71(s,2H),4.29-4.07(m,2H),3.91(s,3H),3.90(s,6 H),2.98(td,J=6.6,2.1Hz,2H),2.05(t,J=6.2Hz,2H).13C NMR(100MHz,CDCl 3)δ:161.76,161.49,159.29,153.06,151.05(d,J=2.3Hz),144.28,138.52,135.48,131.6 7,129.67(d,J=8.0Hz),129.17,122.93(d,J=24.3Hz),121.15(d,J=8.6Hz),111.3 6(d,J=23.5Hz),107.51,60.98,56.26,42.38,25.85,22.04.MS-ESI m/z:calcd for C22 H21FN2O4[M+H]+:397.1485;found:397.1504.
BLG21:(E)-6-(benzo[d][1,3]dioxol-5-methylene)-2-fluoro-6,7,8,9-tetrahydro-11H-pyrido[2,1 -b]quinazolin-11-one;Yield:84%;yellow solid,m.p.232-234℃;1H NMR(400MHz,CD Cl3)δ:8.11(s,1H),7.89(dd,J=8.6,3.1Hz,1H),7.75(d,J=7.9Hz,1H),7.54-7. 42(m,1H),7.01(d,J=8.9Hz,2H),6.88(d,J=8.0Hz,1H),6.02(s,2H),4.16(t,J =5.9Hz,2H),3.07-2.84(m,2H),2.11-1.91(m,2H).13C NMR(100MHz,CDCl3) δ:161.73,161.43,159.26,151.45,147.82,147.78,135.54,130.27,129.57,129.47,125.20, 122.96(d,J=24.3Hz),121.04(d,J=8.7Hz),111.38(d,J=23.5Hz),109.81,108.45, 101.39,42.24,25.88,22.02.MS-ESI m/z:calcd for C20H15FN2O3[M+H]+:351.1067;fo und:351.1123.
BLG22:(E)-2-fluoro-6-(4-fluorobenzylidene)-6,7,8,9-tetrahydro-11H-pyrido[2,1-b]quinazolin -11-one;Yield:75%;yellow solid,m.p.183-185℃;1H NMR(400MHz,CDCl3)δ:8.16 (s,1H),7.90(dd,J=8.5,3.0Hz,1H),7.72(dd,J=9.0,4.9Hz,1H),7.51-7.41(m,3 H),7.12(t,J=8.6Hz,2H),4.20-4.12(m,2H),2.97-2.88(m,2H),2.11-1.91(m,2 H).13C NMR(100MHz,CDCl3)δ:163.70,161.80,161.43(d,J=3.6Hz),161.22,159. 34,151.01(d,J=2.4Hz),144.15,134.30,132.26(d,J=3.5Hz),131.80(d,J=8.2H z),129.66(d,J=8.1Hz),129.49,122.96(d,J=24.4Hz),121.19(d,J=8.7Hz),115.5 4(d,J=21.5Hz),111.38(d,J=23.5Hz),42.37,25.65,21.98.MS-ESI m/z:calcdfor C19H14F2N2O[M+H]+:325.1074;found:325.1153.
上述得到的Isaindigotone衍生物BLG01-22的结构式如下表1所示。
表1 Isaindigotone衍生物的结构式
实施例2 Isaindigotone衍生物对不同人类癌细胞系的体外抗癌活性
通过MTT法研究了22种Isaindigotone衍生物对不同人类癌细胞系(包括AGS、HCT116、SMMZ-7721和PANC-1)的体外抗癌活性,顺铂用作阳性对照。具体方法为:
取不同癌细胞于96孔板(1×104个细胞/100μL)中培养,37℃预孵育12h,使其贴壁。 细胞与不同剂量的化合物孵育48h;处理后,每孔加入10μL的MTT溶液(5mg/mL), 37℃继续孵育4h;弃去培养基,每孔加入100μL的DMSO,然后通过酶标仪(Spectra Max190,美国)通过在波长490nm处读取每个孔的OD值来确定衍生物的IC50值。
Isaindigotone衍生物和顺铂阳性对照对四种不同癌细胞48小时的IC50值见表2。结果表 明:①与其他癌细胞相比,胃癌细胞AGS对大多数Isaindigotone衍生物表现出更高的敏感性, IC50为1.96-44.50μM;尤其是化合物BLG04、BLG06显示出比Isaindigotone本身更高的抑 制活性,其IC50分别为1.96μM、2.23μM、2.09μM;化合物BLG18显示出与Isaindigoton e相似的活性,IC50为6.79μM;②与Isaindigotone相比,BLG06在AGS细胞中的抗癌活性 提高了近4倍,与顺铂相比,BLG06对AGS细胞的抗癌活性是顺铂的10倍;③与Isaindigo tone相比,BLG03、BLG06、BLG11、BLG13、BLG15、BLG18、BLG21对于胰腺癌细胞PANC-1也表现出显着的细胞毒性,其中BLG06对胰腺癌细胞PANC-1的IC50为9.94μM,活 性是Isaindigotone的5倍;④与Isaindigotone相比,BLG06、BLG06、BLG18对于结直肠癌 细胞HCT116也具有显著的抑制活性,其中BLG18对结直肠癌细胞HCT116的IC50为2.80 μM,其抑制活性为Isaindigotone的20倍以上;对于肝癌细胞SMMZ-7721,大多数Isaindigo tone衍生物显示出中等的细胞毒活性。
综上所述,本发明所述Isaindigotone衍生物对AGS、HCT116、SMMZ-7721和PANC-1癌细胞均具有一定的抑制活性。
表2 Isaindigotone衍生物BLG01-22对各种肿瘤细胞的IC50(μM)
实施例3 Isaindigotone衍生物BLG06对胃癌的抑制活性
1.BLG06的体外抗增殖活性
使用MTT法(同实施例1)测定在24h、48h和72h时,BLG06对胃癌AGS细胞系 和胃表皮细胞GES细胞系的抑制活性。
结果如图2所示,与对照组相比,BLG06对胃癌AGS细胞具有显著的抑制作用,且胃癌AGS细胞活力以剂量和时间依赖性方式受到显着抑制;同时BLG06对正常胃表皮细胞GES-1表现出良好的安全性。
2.BLG06对胃癌AGS细胞形态的影响
为了进一步确定生长抑制是否由细胞凋亡引起,使用Hoechst 33258染色来可视化核形 态。具体方法为:
将AGS细胞接种在24孔板的腔室载玻片上,并用不同浓度的化合物BLG06处理48h。根据制造商的说明(Solarbio life sciences,China),在室温下用4%多聚甲醛固定30min, 然后用PBS洗涤细胞3次,并与100:1稀释的Hoechst 33258(10μg/mL)一起孵育在室温 下10min。再次洗涤载玻片并在荧光显微镜(Zeiss,德国)下检查。
结果如图3所示,荧光显微镜检查显示处理后的AGS细胞表现出典型的形态变化,如染 色质凝聚和细胞收缩;该结果表明BLG06能够诱导AGS细胞凋亡。
3.BLG06对AGS细胞周期的影响
为了进一步确定BLG06诱导细胞增殖抑制的潜在机制,将AGS细胞用不同浓度的BLG 06处理24h并用PI染色。用流式细胞术分析细胞周期分布。具体方法为:
将AGS细胞(7×105/孔)接种在6孔板中并用DMSO或不同浓度的BLG06处理。然后收获细胞,用冷PBS洗涤,在4℃用70%乙醇固定并再次用PBS洗涤3次。之后,将细胞重 新悬浮在100RNase A中,并在37℃下孵育30min,以用400μL碘化丙啶染色。最后通 过流式细胞仪(BD LSRFortessa,America)分析DNA含量。
结果如图4中A和B所示,各期AGS细胞比例与对照组相比差异不大。说明,BLG06 不能阻滞AGS细胞周期。
4.BLG06对AGS细胞凋亡的影响
由于BLG06引起AGS的显着形态变化和高死亡率,进行Annexin-V/PI染色以进一步确 定BLG06是否可以诱导细胞凋亡。凋亡细胞中磷脂酰丝氨酸的易位使膜联蛋白V-FITC(一 种荧光素活性染料)能够与之结合。PI可以穿透破损的膜并与DNA结合。因此,Annexin-V /PI染色可以将活细胞与凋亡细胞和坏死细胞区分开来。具体方法为:
AGS细胞接种在六孔板上,并与化合物BLG06(2.0μM、3.0μM、4.0μM和5.0μM) 一起孵育48h;然后将细胞悬浮在100μL稀释的结合缓冲液中,将细胞浓度调整为1×106细胞/mL,并加入5μL Annexin-V-荧光素;在25℃下将混合物在黑暗中孵育5min后,加 入10μL碘化丙啶和400μL PBS;使用流式细胞仪(BD LSRFortessa,美国)进行测量。
结果如图4中C和D所示,经BLG06处理后,AGS细胞早期凋亡的百分比从0.91%增加到6.24%,晚期凋亡率从3.24%增加到30.40%,且早期凋亡细胞和晚期凋亡细胞的变异均 呈剂量依赖性。表明BLG06能够诱导AGS细胞凋亡。
5.BLG06对线粒体(MMP)膜电位变化的影响
进一步研究了BLG06对AGS细胞中MMP的影响。具体方法为:线粒体膜电位的检测是使用JC-10试剂盒(Solarbio Invitrogen Corp.,北京,中国)测定。将AGS细胞接种在2 4孔板的盖玻片上并孵育24h;将细胞用不同浓度的BLG06(2.0μM、3.0μM、4.0μM和 5.0μM)再处理24h,然后用4%多聚甲醛固定;PBS洗涤3次后,JC-10 37℃染色20mi n;用羰基氰化物-3-氯苯腙(CCCP,10.0μM)处理的细胞用作阳性对照;结果是通过激光 共聚焦荧光显微镜(Zeiss,德国)获得的。
结果如图5所示,CCCP作为阳性对照,当AGS细胞用不同浓度的BLG06(2.0μM、3. 0μM、4.0μM和5.0μM)处理时,观察到MMP以剂量依赖性方式明显减少。实验结果表 明BLG06诱导的AGS细胞凋亡与线粒体介导的通路有关。
6.分子对接
为了进一步探索分子靶点,进行了分子对接以评估BLG06是否是一种有效的PI3K/AK T/mTOR抑制剂。对于AKT蛋白,天冬氨酸292上的羧基阴离子与配体形成负相互作用。 由于其氨基阳离子,赖氨酸268与配体形成正相互作用。苏氨酸211和苏氨酸291、天冬酰 胺53和天冬酰胺54以及谷氨酰胺79作为极性氨基酸与配体形成强极性相互作用。这些对 接结果提供了对蛋白质-配体相互作用和进一步结构修饰以提高活性的重要依据。为了进一步研究分子机制,我们通过蛋白质印迹分析检测了BLG06对线粒体依赖性通路相关因子Bax和Bcl-2以及凋亡效因子caspase-3激活的影响。具体方法为:
细胞培养:细胞记数,接种,培养在六孔板中,长至100万个细胞后,取出,裂解,细胞被收集后,加入8μL细胞裂解液,提取上清总蛋白液。使用BCA法检测总蛋白浓度,后 变性蛋白样品,取相同质量的蛋白上样,SDS-PAGE胶电泳分离蛋白条带。根据目标蛋白计 算分子量,将相应位置的电泳胶条带切下,湿转法将蛋白条带转到PVDF膜上。
配置TBST缓冲液:25mM NaCl,100mM Tris,0.2%Tween-20,pH 7.4,用TBST 缓冲液溶解的5%脱脂奶粉溶液(w/v)封闭PVDF膜。分别相应用一抗和二抗孵育PVDF膜, TBST缓冲液漂洗适当次数后,使用SuperECL Plus超敏发光试剂盒显色成像。
结果如图6所示,BLG06处理48h后,Bax和cleaved-caspase-3蛋白表达水平显着升高, Bcl-2蛋白表达水平逐渐降低。表明BLG06通过线粒体相关途径影响AGS细胞的凋亡。
7.BLG06对PI3K/Akt/mTOR信号通路的影响
为了进一步评估BLG06是否影响PI3K/AKT/mTOR信号通路,据报道与细胞凋亡有关, 进行了蛋白质印迹分析以检查相关蛋白质的变化。Akt的磷酸化水平是PI3K/Akt/mTOR信号 通路的重要标志之一,因此选择AGS的BLG06来测试其在2.00μM浓度下对Akt磷酸化(Ser 473)的抑制作用,持续48h。具体方法为:为了获得含有总蛋白的细胞裂解物,用RIP A裂解液裂解AGS细胞;使用Bradford测定法定量蛋白质的浓度;将样品施加到10%SDS- PAFE(十二烷基硫酸钠-聚丙烯酰胺凝胶电泳)上,转移到PVDE(聚偏二氟乙烯)膜上; 然后将膜浸入含有5%脱脂牛奶的TBST(Tris缓冲盐水和吐温)中,轻轻搅拌1h,并在4℃ 下与一抗(GAPDH#60004-Ig,购自Proteintech;AKT#YT0185;p-AKT#YP0006;mTO R#YT2913,购自ImmunoWay;PI3K#YP0176,购自Affinity;Bcl-2#bs-0032R、Bax#bs- 0127R、Caspase-3#bs-0081R,购自Bioss);之后,将膜与HRP标记的(辣根过氧化物酶) 二抗在室温下孵育2h,并在照相胶片上检测;最后,用ImageJ软件分析蛋白质的条带。
结果如图6所示,BLG06可以显着降低Akt的磷酸化。此外,BLG06下调AGS细胞系 中PI3KCmTOR蛋白的表达,这表明BLG06能够影响PI3K/Akt/mTOR信号通路的功能,是 一种潜在的AKT蛋白抑制剂。
8.BLG06抑制AGS细胞迁移
通过Transwell迁移试验评估了BLG06抑制AGS细胞迁移的能力。具体方法为:为了分 析迁移活性,应用了具有8μm孔膜的transwell装置;将细胞以3×104个细胞/100μL的密度培养并悬浮在无血清RPMI-1640培养基中;将细胞悬浮液接种到含有Solarbio Matrigel(8 μm孔径;Corning)的装置的上室,然后接种600.0μL的20%FBS培养基;培养48h后, 分别用4%多聚甲醛固定细胞,并用0.1%结晶紫染色10min;使用光学显微镜对膜进行拍照。 结果如图7所示,与对照组相比,BLG06能够显着减少迁移到腔室底层的细胞数量。表明B LG06可以阻止AGS细胞的迁移。
Claims (8)
1.一种Isaindigotone衍生物或其药学上可接受的盐,其特征在于,所述Isaindigotone衍生物结构式如下式(I)所示:
其中,所述n为1,R1、R2和R4为氢,R3和R5为三氟甲基;
或,所述n为1,R1为氢,R2为氟,R3、R4和R5为甲氧基;
或,所述n为1,R1和R4为氢,R2为氟,R3和R5为三氟甲基;
或,所述n为1,R1和R5为氢,R2、R3和R4为氟;
或,所述n为1,R1、R3和R4为氟,R2和R5为氢;
或,所述n为1,R1和R2为甲氧基,R3和R5为氢,R4为氟或三氟甲基;
或,所述n为2,R1和R2为氢,R3和R5为甲氧基,R4为羟基;
或,所述n为2,R1为氟,R2和R5为氢,R3和R4形成1,3-二氧五环。
2.如权利要求1所述的Isaindigotone衍生物或其药学上可接受的盐在制备治疗癌症药物中的应用。
8.如权利要求1所述的Isaindigotone衍生物或其药学上可接受的盐,加入药学上可接受的辅料制成药学上可接受的任一剂型。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110808629.9A CN114249733B (zh) | 2021-07-16 | 2021-07-16 | 一种Isaindigotone衍生物及其在制备抗肿瘤药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110808629.9A CN114249733B (zh) | 2021-07-16 | 2021-07-16 | 一种Isaindigotone衍生物及其在制备抗肿瘤药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114249733A CN114249733A (zh) | 2022-03-29 |
CN114249733B true CN114249733B (zh) | 2023-05-12 |
Family
ID=80791198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110808629.9A Active CN114249733B (zh) | 2021-07-16 | 2021-07-16 | 一种Isaindigotone衍生物及其在制备抗肿瘤药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114249733B (zh) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101857595B (zh) * | 2010-05-21 | 2012-11-21 | 中山大学 | 一种喹唑酮衍生物及其制备方法和作为抗癌药物的用途 |
CN105272986A (zh) * | 2015-06-15 | 2016-01-27 | 厦门医学高等专科学校 | 一种可抑制乙酰胆碱酯酶活性的化合物或其制备方法和应用 |
CN106220631B (zh) * | 2016-07-26 | 2019-02-05 | 中山大学 | 一种7位氟取代Isaindigotone衍生物及其制备方法和在制备抗癌药物中的应用 |
-
2021
- 2021-07-16 CN CN202110808629.9A patent/CN114249733B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN114249733A (zh) | 2022-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6346628B2 (ja) | Stat3経路阻害剤および癌幹細胞経路阻害剤の新規のグループ | |
Reddy et al. | 4β-amidotriazole linked podophyllotoxin congeners: DNA topoisomerase-IIα inhibition and potential anticancer agents for prostate cancer | |
Chen et al. | Novel nicotinoyl pyrazoline derivates bearing N-methyl indole moiety as antitumor agents: Design, synthesis and evaluation | |
Zhou et al. | Synthesis of 6-cinnamoyl-2H-benzo [b][1, 4] oxazin-3 (4H)-ones and their effects on A549 lung cancer cell growth | |
Gao et al. | Molecular mechanisms of celery seed extract induced apoptosis via s phase cell cycle arrest in the BGC-823 human stomach cancer cell line | |
Ke et al. | Foeniculum vulgare seed extract induces apoptosis in lung cancer cells partly through the down-regulation of Bcl-2 | |
Rui et al. | The dual induction of apoptosis and autophagy by SZC014, a synthetic oleanolic acid derivative, in gastric cancer cells via NF-κB pathway | |
WO2022218362A1 (zh) | 一种硝基呋喃类小分子化合物在制备诱导铁死亡和/或减缓胃癌化疗耐药药物中的应用 | |
WO2021190076A1 (zh) | 一种具有克服顺铂耐药的抗肿瘤化合物及其制备与应用 | |
Han et al. | 8-Cetylcoptisine, a new coptisine derivative, induces mitochondria-dependent apoptosis and G0/G1 cell cycle arrest in human A549 cells | |
Su et al. | Novel penta-1, 4-diene-3-one derivatives containing quinazoline and oxime ether fragments: Design, synthesis and bioactivity | |
CN113501819B (zh) | 吡啶并咪唑取代的喹唑啉酮衍生物及其合成方法和应用 | |
Du et al. | Design, synthesis, and cytotoxic activities of isaindigotone derivatives as potential anti-gastric cancer agents | |
Wang et al. | Discovery of 2′-hydroxychalcones as autophagy inducer in A549 lung cancer cells | |
Chen et al. | Cyclometalated Ru (II) β-carboline complexes induce cell cycle arrest and apoptosis in human HeLa cervical cancer cells via suppressing ERK and Akt signaling | |
CN106831812A (zh) | 含联芳基酰胺结构的杂环并嘧啶或吡嗪类化合物及其应用 | |
Liu et al. | Design, synthesis and biological evaluation of novel asperphenamate derivatives | |
US20210263039A1 (en) | Application of niemann-pick c1 protein in diagnosis and treatment of cancer | |
Sun et al. | Design and synthesis of β-carboline derivatives with nitrogen mustard moieties against breast cancer | |
CN110551156B (zh) | 特定基团修饰的n1,n3取代4,5-二芳基咪唑环卡宾铑配合物及其制备方法和应用 | |
CN114249733B (zh) | 一种Isaindigotone衍生物及其在制备抗肿瘤药物中的应用 | |
CN110256364B (zh) | 一种喹唑啉类化合物及其制备方法和用途 | |
Feng et al. | Scaffold hopping of celastrol provides derivatives containing pepper ring, pyrazine and oxazole substructures as potent autophagy inducers against breast cancer cell line MCF-7 | |
CN112110941B (zh) | 一种作为Hippo信号通路抑制剂的化合物 | |
Zhou et al. | Synthesis, biological evaluation and cellular localization study of fluorescent derivatives of Jiyuan Oridonin A |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |